Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
12/07/2017 12/08/2017 12/11/2017 12/12/2017 12/13/2017 Date
19.61(c) 20.18(c) 20.39(c) 20.455(c) 20.395 Last
195 327 408 513 249 481 291 007 137 210 Volume
+2.59% +2.91% +1.04% +0.32% -0.29% Change
More quotes
Financials (€)
Sales 2017 64,7 M
EBIT 2017 -56,3 M
Net income 2017 -67,9 M
Finance 2017 203 M
Yield 2017 -
Sales 2018 60,1 M
EBIT 2018 -67,3 M
Net income 2018 -60,6 M
Finance 2018 108 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 20,5x
EV / Sales2018 23,7x
Capitalization 1 528 M
More Financials
Company
Ablynx NV is a is a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand.It offers programs for inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.The company was founded on July 4, 2001... 
Sector
Biotechnology & Medical Research
Calendar
12/12 | 01:30pmPresentation
More about the company
Surperformance© ratings of Ablynx
Trading Rating : Investor Rating :
More Ratings
Latest news on ABLYNX
12/12 ABLYNX : 12/12/2017 ablynx reports additional clinically important benefits of c..
12/12 ABLYNX : Reports additional clinically important benefits of caplacizumab from i..
12/07 ABLYNX : Will host a webcast to discuss additional data from its phase iii hercu..
11/29 ABLYNX : 29/11/2017 publication in accordance with article 14 of the belgian law..
11/29 ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
11/21 ABLYNX : 21/11/2017 results from the phase iii hercules study of caplacizumab fo..
11/21 ABLYNX : Results from the phase iii hercules study of caplacizumab for the treat..
11/16 ABLYNX : 16/11/2017 ablynx announces results for the first nine months of 2017 a..
11/16 ABLYNX : Announces results for the first nine months of 2017 and a year-to-date ..
11/15 ABLYNX : 15/11/2017 publication in accordance with article 14 of the belgian law..
More news
Sector news : Biotechnology & Medical Research - NEC
08:08a REGENERON PHARMACEUTICALS : Sanofi sees nine regulatory submissions over next 18..
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
12/07 Ablynx to update on Phase 3 study of caplacizumab December 12
11/16 Ablynx NV reports 9M results
10/18 YOUR DAILY PHARMA SCOOP : AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
10/17 Ablynx prices $175M U.S. IPO at $20.95
10/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 4, 2017
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 22,9 €
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX86.59%1 794
CELLTRION, INC.--.--%23 085
IQVIA HOLDINGS INC32.70%21 148
INCYTE CORPORATION-5.43%20 523
LONZA GROUP57.44%19 299
ALNYLAM PHARMACEUTICALS, INC.243.83%12 606